1. Home
  2. BA vs AMGN Comparison

BA vs AMGN Comparison

Compare BA & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Boeing Company (The)

BA

Boeing Company (The)

HOLD

Current Price

$224.34

Market Cap

167.8B

Sector

Industrials

ML Signal

HOLD

Logo Amgen Inc.

AMGN

Amgen Inc.

HOLD

Current Price

$348.26

Market Cap

188.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BA
AMGN
Founded
1916
1980
Country
United States
United States
Employees
N/A
N/A
Industry
Aerospace
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
167.8B
188.0B
IPO Year
2005
2000

Fundamental Metrics

Financial Performance
Metric
BA
AMGN
Price
$224.34
$348.26
Analyst Decision
Strong Buy
Hold
Analyst Count
19
19
Target Price
$254.26
$350.22
AVG Volume (30 Days)
5.9M
2.2M
Earning Date
04-22-2026
04-30-2026
Dividend Yield
N/A
2.87%
EPS Growth
113.51
88.23
EPS
2.48
14.23
Revenue
$89,463,000,000.00
$25,424,000,000.00
Revenue This Year
$12.39
$4.97
Revenue Next Year
$14.31
$2.49
P/E Ratio
$90.17
$24.65
Revenue Growth
34.50
8.83
52 Week Low
$156.47
$265.66
52 Week High
$254.35
$391.29

Technical Indicators

Market Signals
Indicator
BA
AMGN
Relative Strength Index (RSI) 60.51 44.36
Support Level $212.66 $344.95
Resistance Level $225.28 $353.25
Average True Range (ATR) 5.21 7.56
MACD 3.55 0.58
Stochastic Oscillator 97.78 53.89

Price Performance

Historical Comparison
BA
AMGN

About BA Boeing Company (The)

Boeing is a major aerospace and defense firm operating in three segments: commercial airplanes; defense, space, and security; and global services. Boeing's commercial airplanes segment competes with Airbus in the production of aircraft that can carry more than 130 passengers. Boeing's defense, space, and security segment competes with defense contractors such as Lockheed Martin and Northrop Grumman to create military aircraft, satellites, and weaponry. Global services provides aftermarket support to airlines.

About AMGN Amgen Inc.

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Share on Social Networks: